Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker

US10620207B2 · kind B2 · utility

Assignee

• Ventana Medical Systems, Inc. · US

Inventors

• Thomas Grogan · Tucson, US
• Hiro Nitta · Tucson, US
• Michael Barnes · Oro Valley, US
• Penny Towne · Tucson, US
• Shalini Singh · Tucson, US
• June F. Clements · Tucson, US
• Crystal Schemp · Tucson, US
• Esteban Roberts · Tucson, US

Key dates

• Filing date: Mar 31, 2017
• Grant date: Apr 14, 2020
• Expiry date: Sep 3, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.